Independent company/product valuation reports by our experienced Life Sciences experts
The typical private investment process comes with a negotiation between the company and the possible investor. It can be challenging to determine a product or company value, especially when it comes to high-risk product development. For example, the development of drug therapies or medical technology products require a large amount of funding and comes with a high risk. Although there are various valuation methods available, Catalyze focuses on the risk-adjusted net present value method (rNPV method), which is seen as “the golden standard” in life sciences.
What can we do for you?
Catalyze provides both companies and investors independent company or product valuation reports. The valuations are performed by our experienced life sciences valuation experts. In addition, Catalyze performs valuations for investment funds, leveraging its expertise in life sciences technology, financial forecasting, and risk-assessment. With a client portfolio of 2000+ companies, Catalyze is the most experienced partner to value your company or product.
Interested in learning more?
Get in touch today and have all your questions answered by one of our experts
Wouter
+31 (0)6 46 87 39 24
A must-have if you’re interested in getting your business to the next level